Women’s health tech startup Elvie has added £12.7 million through a Series C funding round, bringing its total raised funds to £70 million ($97 million). The 2013-founded, U.K.-based startup previously raised a $42 million Series B in 2019, and a $6 million Series A in 2017.

Read more: Elvie’s Silent Wearable Breast Pump Makes Life Easier for Nursing Mothers

Elvie revealed that existing investors Hiro Capital, Westerly Winds, and IPGL, along with the co-founders of Blume Equity, a private equity firm focused on the food and health industries, have injected funds into the Series C extension. According to Frost and Sullivan, the femtech industry is expected to become a $50 billion market by 2025. Elvie said it will use the money to accelerate growth by geographically expanding and entering new markets as well as to diversify its product offerings to target other "key stages" in women's lives.

That means it’ll be splurge on R&D to support product development – connected hardware that mixes physical gadgetry with software still looks to be a strong focus – and also on strengthening its ops and infrastructure to prep for further scale, reports TechCrunch.

Elvie sells four products at this stage. The first to launch, Elvie Trainer, is an award-winning Kegel trainer and app. Its second product, Elvie Pump, is the world’s first silent, wearable breast pump. The newest additions to the line-up are Elvie Curve and Elvie Catch; both enhancing the Elvie breastfeeding range. “Elvie is ready for the next phase of our growth. We have already revolutionized the categories we operate in, but we know that there is vast untapped potential to create better technology products and services for women in new areas,” said Tania Boler, CEO and founder of Elvie.

Read more: Femtech Hardware Elvie Partners with NHS to Tackle Stress Urinary Incontinence

She added that Elvie’s goal is to create “the go-to destination for women’s health at all life stages” – selling “sophisticated, accurate and personalized solutions” to its target female consumer.

Chinese electronics manufacturer TCL has launched its NXTWEAR G Smart glasses. Teased at CES 2021 in January, the TCL NXTWEAR G combines dual Sony micro OLED screens with portability, plug-and-play functionality, and a stylish, comfortable design. Additionally, TCL also launched its new cross-device Multi-Screen Collaboration feature across select lines. The feature delivers seamless productivity across several product categories, including select TCL Mobile devices and compatible, laptops, tablets, and televisions.

Read more: CES 2021: TCL Announces its First Wearable Display, True Wireless Earbuds and Pet Tracker

Aaron Zhang, CEO at TCL Communication, said: "With TCL's expertise in Display Greatness, now is the perfect time to challenge the established, disconnected, single-screen scenario across price points. In the premium space, NXTWEAR G Smart Glasses become an extension of your smart device and transport you to a private viewing party wherever you are. Looking at its broader portfolio, TCL's accessibly priced high-end devices, including the TCL 20 Pro 5G, will provide even more value in the coming months, with rich Multi-Screen Collaboration rolling out in future software updates."

TCL NXTWEAR G

Experience smart vision with TCL NXTWEAR G Wearable Display Glasses, a portable cinema for movie lovers, an immersive world for gamers, or a private space at home, work, or on your commute. Combining a sophisticated, foldable frameless design with a comfortable fit, NXTWEAR G showcases a stylish, reflective deep black exterior and a high-end look and feel.

Convenient and compact, NXTWEAR G is protected by a capsule case that fits in a small backpack or large handbag. No charging is required; the grab-and-go glasses are plug-and-play, so can be powered by your compatible laptop, tablet, or smartphone. This creates a unique, fuss-free watching environment when matched with technology you already own, the company said in a press release.

The dual 1080p high-definition Sony FHD Micro OLED panels are perfectly positioned to deliver home theatre proportions, as NXTWEAR G emulates a 140-inch display with a 16:9 aspect ratio. With a visual experience supporting 3D 4K content integrated with stereo speakers, cinema scores and gameplay are brought to life as you lose yourself in sensory immersion. The streamlined, reflective deep black exterior of the TCL NXTWEAR G is set against soft-touch nylon and silica gel – carefully selected materials surrounding a metallic frame, creating a comfortable, skin-friendly fit and feel that's also durable. Inside its carry case are three adjustable nose pad sizes to cater to every face shape as well as a lens adapter for a clear viewing experience no matter what your prescription might be.

The NXTWEAR G's open-fit design maintains a degree of peripheral vision, so you can shift your gaze down to glance at your fingers typing on a keyboard or look up to greet a flight attendant offering you an in-flight beverage.

Worn exactly like a traditional pair of glasses, there are no overhead straps to mess up your hair, batteries that need charging, or slots for you to slide a smartphone into with NXTWEAR G. You also don't need an app; simply connect the glasses to any smart device with a compatible USB-C display-out port and put them on for a fantastic visual experience.

NXTWEAR G is compatible with more than 100 smartphones, hybrid two-in-one devices, and laptops from all major manufacturers, and will be available to buy in Australia beginning next month, with market availability to follow in select regions.

Read more: TCL Patent Hints at a Foldable Smartphone that Can be Worn as a Smartwatch

Multi-Screen Collaboration

TCL's Multi-Screen vision starts with whatever device you have on you. As an example, when you're traveling for work, you walk to the train station and buy tickets using contactless payments on your phone, streaming music over 5G as you go. Once in your seat, the handoff from your TCL 20 Pro 5G to a cinematic wearable, the NXTWEAR G, as a portable big-screen experience transports you instantly while you rest and recharge.

Multi-Screen Collaboration will be supported across a range of product lines, rolling out initially to TCL 20 Pro 5G smartphones through an over-the-air software update.

Sila Nanotechnologies, a next-generation battery materials company, is bringing to market the most significant breakthrough in battery chemistry in 30 years — the technology to replace graphite anodes — which will usher in a new era of energy storage. Sila’s silicon anode chemistry dramatically increases the energy density of batteries, reducing battery size without sacrificing safety or performance. Sila’s new battery is now commercially available in WHOOP 4.0, the latest fitness and health wearable from WHOOP.

Read more: WHOOP Acquires Sports Tech Startup PUSH To Unlock Deeper Strength-Training Insights

The Sila anode is the first next-gen lithium-ion material available on the market. Designed to offer economical manufacturing at a global scale, our unique technology is poised to electrify the future, while delivering transformational benefits to the mobile industry today.

• 20% more energy density
• Drop-in solution for ease and speed to market
• Smaller battery footprint
• No compromise in cycle life, charge performance, or safety

The technology also facilitates the development of new and unique product features for mobile devices not previously possible due to energy density and battery size constraints - better cameras, augmented reality/virtual reality sensors, wireless charging, 5G speeds, and sensors for continuous health monitoring, reports BusinessWire.

“After 10 years, 55,000 iterations, and over a 1,000x manufacturing scale up, the Sila team is the first to industrialize and now make commercially available a new type of lithium-ion chemistry with dramatically higher energy density. Our next-generation materials will drive radical change in product innovation, freeing consumers and device makers from having to choose between better design, more features, and battery performance,” said Gene Berdichevsky, CEO and Co-Founder of Sila. “We are running out of time to transition from the fossil fuels economy to the energy storage economy. The path to a sustainable future will be paved with great products and Sila is proud to be enabling those products today.”

WHOOP 4.0, the most advanced 24/7 fitness and health wearable, is the first product in the market to use next-generation silicon anode materials. Powered with Sila science, WHOOP 4.0 is a smaller, sleeker product with 17 percent higher energy density—enabling a 5-day battery life and enhanced sensors for improved fitness tracking. These advances were achieved without altering existing manufacturing processes, making it faster and easier for WHOOP and its battery manufacturing partner to incorporate Sila materials into its newest wearable.

Read more: Apple Watch’s Future Band Design Could Boost Battery Life

“One of the greatest barriers to advancing the design of wearable technologies has been the weight and size of the battery technology available,” said John Capodilupo, Co-Founder & Chief Technology Officer at WHOOP. “With Sila, all that has changed. We’ve been able to transform WHOOP 4.0 from its previous version and load it with new features and capabilities, without battery performance compromise. Just as we have leveraged this new battery advancement to push the wearable industry forward, Sila’s technology has the potential to enable exciting design innovation in other categories and products.”

Facebook, Inc. and Ray-Ban have teamed up to launch the next generation of smart glasses, Ray-Ban Stories. The highly anticipated collaboration brings forward a new way to seamlessly capture, share and listen through your most authentic moments. The announcement was made today by Mark Zuckerberg and Rocco Basilico in a virtual announcement detailing the partnership and the exciting capabilities.

Read more: Bose Announces Frames – Revolutionary Smartglasses that Combine Sunglasses, Wireless Headphones and Audio Augmented Reality

“Today we’re excited to launch Ray-Ban Stories: Smart glasses that give you an authentic way to capture photos and video, share your adventures, and listen to music or take phone calls — so you can stay present with friends, family, and the world around you,” Facebook said.

Leading Ray-Ban Stories’ product lineup with the most recognizable style, an icon since the 1950s is Wayfarer and Wayfarer Large. Facebook and EssilorLuxottica, Ray-Ban’s parent company, were able to engineer smart technology to support all-day wear, including an optimized Snapdragon processor, without compromising style, comfort, and aesthetic, but most of all the weight, with just 5gr more than a standard pair of Ray-Ban Wayfarer.

Ray-Ban Stories include a dual integrated 5MP camera to capture photos and video; discreet open-ear speakers to listen, and a three-microphone audio array to deliver rich voice and sound transmission for calls and videos. You can also find Ray-Ban Stories in a variety of other iconic styles such as the legendary, retro Round and the super iconic Meteor. Starting at $299 (CAD 369, EUR 329, GBP 299, AUD 449) you can add flare to your style by choosing various lenses: sun, prescription, polarized, gradient, Transitions®, and clear, Luxottica said in a press release.

In addition to an iconic design built with innovative technology, Ray-Ban Stories launches in conjunction with a companion app, Facebook View (iOS and Android), creating an easy way to import, edit, and share content captured on the smart glasses with the ability to upload on any social app stored on your phone: Facebook, Instagram, WhatsApp, Messenger, Twitter, TikTok, Snapchat, and more.

“We are incredibly proud to bring Ray-Ban Stories to life with our partners at Facebook,” said Rocco Basilico, Chief Wearables Officer at EssilorLuxottica. “This is a milestone product that proves consumers don’t have to choose between technology and fashion - they can live in the moment and stay connected while wearing their favorite style of Ray-Ban. Our unique approach, combining decades of superior craftsmanship, a dedicated spirit of innovation, and a commitment to delivering only cutting edge technology has resulted in a wearable that people will truly love wearing.”

“Ray-Ban Stories is designed to help people live in the moment and stay connected to the people they are with and the people they wish they were with. EssilorLuxottica has been nothing short of stellar in this partnership and through their commitment to excellence we were able to deliver on both style and substance in a way that will redefine the expectations of smart glasses. We're introducing an entirely new way for people to stay connected to the world around them and truly be present in life's most important moments, and to look good while doing it,” said Andrew Bosworth, Vice President, Facebook Reality Labs.

Read more: Huawei Partners Up with Gentle Monster to Release New Smartglasses

Starting at $299 USD and available in 20 style combinations, the smart glasses are available for purchase online and in select retail stores in the US as well as Australia, Canada, Ireland, Italy, and the UK at Luxottica retail banners including SunglassHut, LensCrafters, OPSM, David Clulow and Salmoiraghi & Viganò and soon after available also at selected wholesale clients.

Flexible electronics have opened up some interesting possibilities. Wearable sensors, for example, are evolving rapidly. New innovations have taken wearable sensors to another dimension. Engineers can now print sensors directly on the skin, taking the form of tattoo-like films and sleeves that monitor various aspects of human health.

Read more: Printed Electronics Paves the Way for Bandages, Electric Tattoos and Biosensors

Scientists at Penn State University have developed new types of sensors that they say can be safely printed directly onto the skin, where it can track things like body temperature and blood oxygen levels, before being washed off once the job is done.

“The sensors are capable of precisely and continuously capturing temperature, humidity, blood oxygen levels, and heart performance signals,” the researchers say. They also linked the on-body sensors into a network with wireless transmission capabilities to monitor the combination of signals as they progress. The sensors can be printed directly onto the skin using a process developed by the research team that bonds a sensor’s metallic components at room temperature, rather than at the high temperatures required by other bonding or sintering processes. High-temperature sintering is normally required to bond silver nanoparticles together into flexible electronic components. At 572 degrees Fahrenheit (300 Celsius), this cannot be safely performed directly on the skin.

The research team invented a technique that bonds a sensor’s metallic components at room temperature, rather than at the high temperatures required by other bonding or sintering processes. They developed a sintering layer, consisting of a commonly used polyvinyl alcohol paste and calcium carbonate, that lets the nanoparticles bond at room temperature.

“The room temperature sintering aid layer consists of polyvinyl alcohol paste — the main ingredient in peelable face masks — and calcium carbonate, which comprises eggshells,” the researchers said.

The layer reduces printing surface roughness and allows for an ultra-thin layer of metal patterns that can bend and fold while maintaining electromechanical capabilities.

Read more: Wearable Sensor With Universal Molecular Recognition Capability, Has Potential Use in Precision Medicine

While this sintering layer allows the process to be completed at room temperature, it also makes the surface of the resulting material smoother and still flexible for on-body applications.

Using the technique, the researchers have already created blood oxygen, ECG, temperature, and humidity sensors directly on the skin. They also linked these sensors into a network that can transmit readings in real-time to a nearby monitor.

The National Football League (NFL) and Amazon Web Services (AWS) today launched a new artificial intelligence challenge to create ways for computers to automatically identify players using NFL game footage. New computer vision models created through the challenge will accelerate the NFL’s work with AWS to better understand, and aim to reduce, injuries in the NFL. Prize money totaling $100,000 will be awarded to data scientists with winning models. The contest will be open through November 2, 2021.

Read more: New Technology Used by NFL Athletes Gives Teams and Trainers Edge in Injury Assessment

This challenge is the next step in the NFL’s work with AWS to develop the Digital Athlete, a virtual representation of an NFL player that can be used to better predict and hopefully prevent player injury. Last season, the NFL hosted its first computer vision competition, providing computer scientists with NFL game data and challenging them to create ways to detect on-field helmet impacts. Nearly 7,800 submissions were received from data scientists around the world. Those solutions are now being used by the NFL and AWS in ongoing work on the Digital Athlete, reports NFL.

This challenge builds upon last season’s competition by scoring teams based on how accurately they identify players involved in a helmet impact. The NFL will be providing data scientists with the same set of game data to build upon the current models. This competition will advance an already robust machine learning pipeline built on AWS that is working towards being among the most advanced and sophisticated injury surveillance and mitigation programs in professional sports.

“This competition is foundational in helping identify each player’s risk to injury-causing events, especially when it comes to head health,” said Jeff Miller, NFL Executive Vice President overseeing the league's health and safety programs. “We are excited to enlist some of the most talented data scientists from around the world to help develop these solutions and meaningfully advance player safety.”

“Using AWS’s broad range of technologies including machine learning (ML) and artificial intelligence (AI), the NFL and AWS will generate more new insights than ever previously possible into player injuries, game rules, equipment, rehabilitation, and recovery,” said Priya Ponnapalli, Senior Manager, Applied Science, Amazon ML Solutions Lab. “This contest will continue that work and the data and insights collected through this project have the potential to shape the future of football.”

Read more: Amazon’s Halo Fitness Tracker Will Soon Be Able To Judge Your Movement Health By Using Your Smartphone Camera

The Digital Athlete will ultimately help the NFL and its clubs to leverage sports science and injury biomechanics to develop individualized training and recovery regimens, conduct real-time risk analysis for injury during games, and identify and evaluate additional player safety initiatives, including around equipment, rules changes, and coaching techniques.

Age-related hearing loss is an increasingly important public health problem affecting approximately 40% of 55–74-year-olds. The primary clinical management intervention for people with hearing loss is hearing aids, however, the majority (80%) of adults aged 55–74 years who would benefit from a hearing aid, do not use them. The reasons include hearing aid value, device factor, appearance, fit and comfort and maintenance of the hearing aid, etc.

Read more: Hearing Aids Market to Grow Up to $14.45 Billion by 2026, According to Fortune Business Insights

Signia’s Active Pro hearing aids are ready to wear, combining iconic user-friendly design similar to premium consumer earbuds with audiological high-tech. This includes Signia Xperience YourSound technology for enhanced speech understanding in noise, Bluetooth connectivity, portable Li-ion rechargeability, and the self-service convenience of the Signia Assistant.

With a next-level hearing aid style comparable to state-of-the-art earbuds, Signia Active Pro looks just like the earbuds that others are wearing.

Signia Active Pro combines the company’s Signia Xperience YourSound technology built on revolutionary acoustic-motion sensors with Li-ion rechargeability and Bluetooth connectivity so the user always hears what matters, with ease.

The pocket-sized Signia Active Charger lets wearers put the devices in and out of their ears when they need them for full flexibility and independence, with up to 26 hours of use per charge.

Wearers enjoy listening to phone calls, music, TV, and more with state-of-the-art Bluetooth streaming. The Active Pro hearing aids connect to your phone over Bluetooth and can double as streaming audio monitors in a pinch.

Read more: Lifestyles of Baby Boomers are Transforming the Way Tech Companies Upgrade Hearing Aids

The latest Signia Xperience platform delivers high-definition prescription audio with technologies found in the most advanced hearing aids. It enables wearers to hear voices clearly from any direction, even in noise.

The Signia Active Pro hearing aids are priced at $3,000 for a pair.

A team of researchers from the Wyss Institute for Biologically Inspired Engineering at Harvard University and the Massachusetts Institute of Technology has found a way to embed synthetic biology reactions into fabrics, creating wearable biosensors that can be customized to detect pathogens and toxins and alert the wearer.

Read more: Respiray: Powerful Wearable Face Mask Alternative Eliminates The Need To Cover Your Face

The team has integrated this technology into standard face masks to detect the presence of the SARS-CoV-2 virus in a patient’s breath. The button-activated mask gives results within 90 minutes at levels of accuracy comparable to standard nucleic acid-based diagnostic tests like polymerase chain reactions (PCR). The achievement is reported in Nature Biotechnology.

“We have essentially shrunk an entire diagnostic laboratory down into a small, synthetic biology-based sensor that works with any face mask, and combines the high accuracy of PCR tests with the speed and low cost of antigen tests,” said co-first author Peter Nguyen, Ph.D., a Research Scientist at the Wyss Institute. “In addition to face masks, our programmable biosensors can be integrated into other garments to provide on-the-go detection of dangerous substances including viruses, bacteria, toxins, and chemical agents.”

The SARS-CoV-2 biosensor is the culmination of three years of work on what the team calls their wearable freeze-dried cell-free (wFDCF) technology, which is built upon earlier iterations created in the lab of Wyss Core Faculty member and senior author Jim Collins. The technique involves extracting and freeze-drying the molecular machinery that cells use to read DNA and produce RNA and proteins. These biological elements are shelf-stable for long periods of time and activating them is simple: just add water. Synthetic genetic circuits can be added to create biosensors that can produce a detectable signal in response of the presence of a target molecule, writes Lindsay Brownwell in Wyss Institute.

The wFDCF face mask is the first SARS-CoV-2 nucleic acid test that achieves high accuracy rates comparable to current gold standard RT-PCR tests while operating fully at room temperature, eliminating the need for heating or cooling instruments and allowing the rapid screening of patient samples outside of labs.

The new face mask can quickly diagnose COVID-19 from the virus in a patient's breath, and can also be integrated into clothing to detect a wide variety of pathogens and other dangerous substances. Credit: Wyss Institute at Harvard University।

In their paper, the researchers demonstrate that a network of fiber optic cables can be integrated into their wFCDF technology to detect fluorescent light generated by biological reactions, indicating the detection of the target molecule with a high level of accuracy. This digital signal can be sent to a smartphone app that allows the wearer to monitor their exposure to a vast array of substances.

Read more: LG Launches PuriCare, A Rechargeable Wearable Air Purifier Mask

“This technology could be incorporated into lab coats for scientists working with hazardous materials or pathogens, scrubs for doctors and nurses, or the uniforms of first responders and military personnel who could be exposed to dangerous pathogens or toxins, such as nerve gas,” said co-author Nina Donghia, a Staff Scientist at the Wyss Institute.

The team is actively searching for manufacturing partners who are interested in helping to enable the mass production of the face mask diagnostic for use during the COVID-19 pandemic, as well as for detecting other biological and environmental hazards.

Health technology startup Ultrahuman has raised $17.5 million in a series B funding round backed by Alpha Wave Incubation (AWI), Steadview Capital, and existing backers Nexus Venture Partners, Blume Ventures, and Utsav Somani’s iSeed fund. Marquee founders and angel investors also participated including Tiger Global’s Scott Schleifer, Sandeep Singhal, Kunal Shah, Sujeet Kumar, Deepinder Goyal, Gunjan Patidar, Gaurav Munjal, Revant Bhate, Mohit Gupta, Vikram Dhingra, and Roman Saini.

Read more: Biomarker Technologies Market Expected To Grow At 12.4% Reaching Over US$ 117,853 Mn by 2027

The new funding brings the total funds raised so far to $25 million. The Bengaluru-based company is committed to making metabolic fitness accessible to millions of people globally. Ultrahuman said it will use the money to improve its biomarker technology and expand globally.

Ultrahuman was started by Mohit Kumar and Vatsal Singhal, who previously founded hyper-local logistics services provider Runnr. It merged with the food delivery app Zomato in 2017 and was a key acquisition for its food delivery aspirations.

Over a billion people in the world suffer from a metabolic health disorder, which contributes to 85 percent of all chronic diseases in the world, the company said in a statement.

“When we started Ultrahuman, we asked ourselves the question 'How does one eat and workout based on the specifics of their own body and their own goals?'. Given there's so much out there around 'what's an ideal diet' or the 'most effective exercise routine' — to figure out how fitness protocols such as eating healthy and exercising lead to better health in a quantifiable way seemed like a big confusing black box,” the company wrote in a statement.

“We wanted to change that by giving people access to a radical new approach—An approach that utilizes biomarkers to tell you how your body reacts to a certain type of food, how to fuel efficiently for exercise, and how to eat for better sleep. Our mission is to help people optimize their health by providing them access to deeply personalized insights and real-time nudges.”

The company’s product branded ‘Cyborg’ is a wearable and subscription service that helps people optimize their exercise and nutrition, based on glucose biomarkers.

Read more: Garmin-Lumen Partnership Launches Second Phase Integration With Metabolic Fitness Data

“Biomarkers will change how the fitness and the healthcare industry works. By being able to continuously monitor their biomarkers like glucose, users can not only avoid chronic diseases but make lifestyle changes that help them improve their fitness levels for longevity and performance,” said Mohit Kumar, founder and CEO, of Ultrahuman.

People at risk of strokes are always on the lookout for signs, but one cannot be alert when they are sleeping. This means thousands of people suffer “wake-up strokes” that are only identified hours after they have occurred. Zeit Medical, a Redwood, CA-based company has developed a brain-monitoring smart headband that constantly monitors the electrical activity of your brain and gets help immediately. This could enable a stroke victim to get to the hospital fast enough to mitigate the stroke’s damage and potentially save lives.

Read more: Ultrasound Wearable Patch Could Provide Early Warning for Heart Attacks and Strokes

“Every minute a stroke goes untreated, two million brain cells are lost, resulting in even worsening disability. Immediate treatment can save brain cells from dying and help to restore brain function. Strokes can occur abruptly in any setting, but strokes are almost impossible to recognize during sleep, as most strokes do not cause pain,” the company says.

Zeit Medical’s device is designed to comfortably monitor the brain's electric activity while you sleep. If it detects a stroke, it will call pre-specified contacts or 911 for you. This will allow you to get treatment right away and finally sleep without anxiety about having a stroke at night.

Just like the presentation of arrhythmia on EKG, neurological injuries induce specific patterns in EEG. Zeit’s technology identifies these signature patterns immediately and enables fast diagnosis and treatment.

A few decades ago, not much could be done to help a stroke victim. In the 1990s, an effective drug came into use, and a little later, a surgical procedure was also introduced. However, both of these treatment required to be administered within a few hours after the onset of the stroke, reports TechCrunch. Orestis Vardoulis and Urs Naber decided to change that. The duo started Zeit, which means ‘time,’ to detect a stroke before it occurs.

“As soon as the stroke hits you, your brain begins to die, so time is of the essence. People have spent millions reducing the time between calling 911 and transportation, and from the hospital door to treatment. but nobody takes care of those hours that pass before the 911 call, so we realized that’s where we have to innovate,” Naber said.

Read more: iRhythm’s Zio Wearable Patch Detects Previously Undiagnosed Atrial Fibrillation, Prevents Stroke

“We hope to see a future where everyone with a stroke risk is issued this device,” Vardoulis told TechCrunch. “We really do see this as the missing puzzle piece in the stroke care continuum.”

WHOOP, the human performance company, announced the acquisition of PUSH, a Toronto-based sports technology startup in a cash and stock transaction. The two wearable technology companies are built on a similar foundation of sports science and physiological research with a shared focus on delivering personalized data, actionable insights, and demonstrable health improvements.

Read more: Golf Fans Can See Players’ Heart Rates Thanks to New Partnership with Whoop

PUSH focuses on velocity-based training data with a sensor that can live in multiple locations on the body to help quantify weightlifting performance via metrics like speed, power, force, and acceleration. PUSH works with hundreds of organizations and sports teams around the world, serving collegiate, professional, and Olympic athletes as well as elite military teams.

“Many of the members and organizations we serve have long asked for additional insight into the physiological impact of weightlifting and functional fitness,” said Will Ahmed, WHOOP Founder and CEO. “The integration of PUSH’s industry-leading strength-training technology into our platform will allow WHOOP to provide even deeper insight into how these activities impact the human body.”

Studies show that WHOOP can positively impact behavior and promote meaningful lifestyle changes through 24/7 continuous heart rate monitoring coupled with insights across sleep, recovery, and strain. With the acquisition of PUSH, the WHOOP platform will be equipped with a more enhanced and robust system of hardware, software, and analytics that provide comprehensive feedback on training activities and wellness, according to a press release.

“Our team has been dedicated to creating cutting-edge technology solutions to help athletes at all levels reach their goals and push human performance forward,” said Rami Alhamad, PUSH Founder and Chief Product Officer. “We are thrilled to join WHOOP and offer our customers a more complete picture of their training.”

WHOOP provides unparalleled insights for improved performance and health to members, government agencies and military teams, professional sports leagues and teams, and numerous other organizations. WHOOP is the Official Fitness Wearable of the PGA TOUR and LPGA Tour, the Official Wearable of CrossFit, and the Official Recovery Wearable of the NFLPA.

About WHOOP

WHOOP provides 24/7 coaching to improve fitness and health. WHOOP members benefit from hardware, a coaching platform designed to optimize behavior, and a community of high performers. WHOOP serves organizations and individuals including professional athletes, Fortune 500 CEOs, fitness enthusiasts, military personnel, frontline workers, and anyone looking to improve their performance.

Read more: How Wearables Like Oura and Whoop Became Pandemic Lifestyle

About PUSH

PUSH maximizes human performance through technology. The PUSH system empowers coaches and trainers to plan, track, assess and improve athlete performance in real-time. The PUSH system consists of a PUSH Band (wearable accelerometer), a Portal, a training management system that coaches use to plan full workout programs and an app that provides athletes with access to programs in the weight room or remotely. PUSH supports coaches and athletes across many sports and levels.

Boston-based virtual care provider Biofourmis dreams of a future where heart failure patients will stay home where they will be remotely monitored via a wearable sensor and an app. The company has now come one step closer to that goal. The FDA for the first time gave the company’s BiovitalsHF® solution a Breakthrough Device designation. BiovitalsHF is a software medical application that augments guideline-directed use of heart failure medications to manage patients in combination with traditional pharmacotherapy.

Read more: Biofourmis Raises $100 Million In Series C Funding To Accelerate Global Expansion

“This important breakthrough designation will help accelerate FDA's final review of BiovitalsHF,” said Kuldeep Singh Rajput, CEO and founder of Biofourmis. “If approved at the end of this expedited process, we look forward to introducing a new virtual heart failure care model that leverages the BiovitalsHF digital therapeutic to improve the use and dosing of Guideline-Directed Medical Therapy among patients with heart failure, for better patient outcomes and reduced healthcare expenditures.”

Heart failure remains the leading cause of hospitalization for patients over age 65. In the U.S., approximately 6.2 million patients live with heart failure, which carries an annual cost that is expected to reach $70 billion by 2030. Guideline-Directed Medical Therapy (GDMT) is a cornerstone of the management of individuals with heart failure with reduced ejection fraction (HFrEF). Timely initiation and dose intensifications of GDMT continue to be a major challenge in realizing clinical trial outcomes in the real world, despite the availability of guidelines from professional societies such as the American Heart Association and the American College of Cardiology, according to a press release.

BiovitalsHF augments clinical decision-making with the goal of personalizing and improving the use and dose of GDMT among patients with HFrEF. The device integrates physiological monitoring, symptoms, signs reporting, patient engagement, medication management, and communication to provide clinicians with personalized and specific medication recommendations. The system alleviates some of the problems that prevent GDMT titration because a) it enables patient health status and drug tolerance to be accurately assessed through continuous physiology monitoring and inclusion of lab assessment results for analysis; b) it reduces clinical inertia by prompting clinicians and patients on medication initiation and up-titration; c) it reduces the burden of clinical visits through a patient-clinician communication system, which becomes essential in circumstances such as a pandemic; and d) it requires fewer resources than nurse-led programs because titration recommendations from the HFrEF management guidelines are distilled in the system.

"The BiovitalsHF digital therapeutic is a software medical application that enables providers to rapidly initiate and intensify life-saving and guideline-recommended medical therapies for patients with heart failure with reduced ejection fraction in a way that is nearly automated," said Maulik Majmudar, MD, cardiologist and chief medical officer and co-founder of Biofourmis. "In a proof-of-concept study, in patients using BiovitalsHF, we demonstrated statistically significant improvements in adherence to GDMT; reduction in levels of the key blood biomarker of heart failure NT-ProBNP; and improvements in health status.”

Read more: Chugai and Biofourmis Collaborating to Develop Digital Solution For Objective Assessment of Pain

Dr. Majmudar added: "BiovitalsHF gets patients on the right therapies faster, which studies have shown helps save lives, prevents emergency department visits and hospital admissions, and enables patients to have a better quality of life. The FDA Breakthrough Devices program was created to help bring the effective treatment of life-threatening or irreversibly debilitating conditions to market sooner, and BiovitalsHF is a perfect candidate for this program due to its clinical importance and impact.”

Vivalink, a specialist in virtual care and digital clinical trials, announced the launch of its enhanced Biometrics Data Platform to accelerate the development and deployment of patient monitoring and data analysis applications for ambulatory and remote settings. Vivalink's Biometrics Data Platform completes the company's end-to-end solution that includes both advanced data services as well as medical wearable sensors.

Read more: Vivalink’s Wearable ECG Monitor Can Now Be Used for 6-Minute Walk Test

As the first real-world evidence data platform of its kind, Vivalink's integrated Biometrics Data Platform is available as a data and insights service platform for digital healthcare solution providers serving the virtual care and drug development markets. The platform is able to accelerate time-to-market by removing the development and regulatory complexities associated with wearable sensors, edge networks, data integration, and data analytics, according to a press release.

The Biometrics Data Platform combines Vivalink's best-in-class medical wearable sensors for continuous and episodic data capture, a clinical patient mobile app, advanced data processing, and machine learning technologies. It's able to automatically collect a continuous stream of vital signs and biometrics in real-world settings such as when the patient is at home or ambulatory and ensures data is delivered successfully from any location for centralized analysis and processing in order to extract clinically relevant insights in real-time or retrospectively.

The patient-friendly sensors integrated into the platform have obtained regulatory clearance in major geographic regions including the USA, EU, and China. Vivalink offers the largest range of reusable sensors for human vital sign monitoring, with recently updated temperature and multi-vital cardiac ECG sensors that have improved usability with an extended data cache, improved battery life, and stronger network connectivity. Such improvements were made based on their years of experience in real-world patient applications. The Vivalink data platform adheres to HIPAA and GDPR and is developed per FDA Design Controls, ISO 13485, IEC 62304, and ISO 14971.

Key features of the Biometrics Data Platform include:

• Wide range of patient-friendly medical wearable sensors for automated continuous data capture of human vital signs and key metrics
• Remote data transfer and synchronization technologies to ensure data ingestion and delivery
• Live and retrospective data access, with raw and filtered data, supported by an advanced biometric data lake for machine learning and AI
• Automated data transformation for clinical database ingestion
• Cloud-based regulatory-cleared, advanced algorithms including automated arrhythmia detection and reporting to generate real-time insights
• Data integration, complete with FHIR support, web services APIs, Webhook support
• Data visualization tools
• Complete systems management of sessions, sensors, and more

Related Vivalink Launches New Turnkey Service for Healthcare Applications in Remote Patient Monitoring

Vivalink (Formerly VivaLNK) has experienced strong adoption of its platform in ambulatory cardiac monitoring, virtual care, and decentralized clinical trials. More than 100 digital healthcare solution partners and customers in 25 countries are delivering a wide range of medical applications based on this platform.

Apple’s next watch may have blood pressure monitoring and a thermometer to help with fertility planning, according to a report by Wall Street Journal.

Read more: The Next Apple Watch May Have A Totally Redesigned Wrap-Around Display

While these features appear to be in the not-so-distant future, the documents reveal that the tech giant has broader ambitions for its smartwatch. The future Apple smartwatches may have the ability to detect sleep apnea, provide medical guidance when it senses low blood oxygen levels, and, perhaps one day, spot diabetes, according to the WSJ article.

According to the report, Apple wants to develop a sensor that can function as a proxy for a blood pressure cuff without squeezing the wrist. The company has been working for a long time on this feature.

If these plans come to fruition, this represents another step in Apple’s healthcare. The Cupertino-based tech giant made headlines in 2018 when it won FDA De Novo approval for its smartwatch with an ECG reader.

Since then, the company has continued to add health features to its smartwatches. In December, MobiHealth reported that Apple was adding a VO2 Max feature on its smartwatches, as well as a new ECG feature that detects Atrial Fibrillation.

Apple’s foray into the femtech space isn’t new. Apple partnered up with Harvard University’s TH Chan School of Public Health on the Apple Women’s Health Study, which aims to understand more about periods in women across demographics and lifestyles.

Other wearables manufacturers are also working on these features. For example, Fitbit added a skin temperature and an FDA-cleared ECG app that detects AFib on the company’s Sense smartwatches.

Read more: Apple Watch Accurately Predicts Frailty in Patients With Cardiovascular Disease

Fitbit is also studying its smartwatches’ ability to measure blood pressure using pulse arrival time, which measures how long it takes for blood to reach a person’s wrist after their heartbeats.

Samsung is another company trying out health features on its smartwatches. Samsung is using an optical heart rate sensor for blood pressure monitoring.

Articulate Labs – an innovative start-up from Dallas, Texas, won the AiQ Smart Clothing Challenge at the 13^th IOT/WT Innovation World Cup. Articulate Labs has developed wearable technology that turns the everyday activity into on-the-go physical therapy and rehabilitation through muscle stimulation and machine learning.

‍

1. INTRODUCE YOURSELF! – HOW DID IT ALL START?

My co-founder, Herbie Kirn, started to develop KneeStim to help manage his own rehabilitation. He lost his right leg in a motorcycle accident over fifteen years ago and quickly wore down the cartilage in the knee of the fully intact leg as he relearned to walk. Told he was too young for knee replacement, but he was advised to go through all of the conservative options available and found braces, injections, and medications each to have unacceptable drawbacks or side effects. What did work for him was physical therapy, with an emphasis on quadriceps strengthening, but didn’t have time for all of the rehabs he needed without impacting work and family responsibilities. While at PT, he was using a neuromuscular electrical stimulation unit while doing leg lifts and started wondering why this process wasn’t more fully automated. What has resulted from quite a bit of trial-and-error in form factor and operating system development is a platform technology that we believe will address unmet knee joint rehabilitation needs for millions and later a multitude of musculoskeletal disorders and a new class of medical devices.

Read more: 13th IoT/WT Innovation World Cup Success Story – PK vitality

‍

2. WHAT ARE THE KEY MILESTONES YOU HAVE REACHED SO FAR?

To date, we have completed a manufacturable/3D-printable version of our device, have earned two letters of interest from hospital systems in Texas, have two paid pilots pending in other countries, have five utility patents granted in the US plus one core patent being nationalized in key European countries. We’ve done all of the above with what’s been largely a two-person team and a (for medical devices) shoestring budget considering we’ve never earned non-dilutive grant funding for research.

‍

3. WHAT WERE THE BIGGEST CHALLENGES YOU HAVE FACED?

I don’t have formal education in business, engineering, or medicine and didn’t feel qualified to serve in this role for a long time. My co-founder had no previous experience with biomechanics or the development of hardware or software to medical technology standards. We both have had to supplement our knowledge and experience with experts in those particular fields and have benefitted greatly from those relationships. Every start-up will be in this situation because there’s no way your initial team, no matter how big or experienced, can have all of the answers instantly. If I had to start this all over again, though, I would do a better job creating value for our advisors and consultants rather than just feeling guilty about asking for help, and I would be more respectfully critical of their work instead of accepting it without question.

‍

4. WHAT IS COMING IN THE NEAR FUTURE?

The next big steps are earning regulatory clearance for our device for sale in the US and abroad, launching our validation studies, and starting to offer our devices to patients. We’re currently building out the We also want to move from what we’re considering an MVP version of our device to something that is lighter and leaner.

‍

5. DESCRIBE YOUR EXPERIENCE IN THE INNOVATION WORLD CUP® AND STANDING AMONGST THE TOP15 WEARABLE AND EBV IOT HERO INNOVATORS 2021?

I felt that the WT/IoT conference was very well organized and that the sessions did a great job addressing challenges unique to the wearable industry. I came away with several relationships that I believe will benefit now with our knee-focused device and in the future as we expand to other joints and conditions. I’m certainly looking forward to participating in future WT/IoT conferences and seeing who we meet next.

6. CAN YOU SHARE WITH US YOUR THREE TIPS FOR UPCOMING START-UPS?

Share your passion – I think part of what distinguishes our company and our work is that it started with a deeply personal unmet need that genuinely couldn’t be addressed by existing means. Our work began to resonate much more with people when we stopped being ashamed of the fact that this device was initially prototyped in an apartment living room with a makeshift machine shop next to a sofa. It’s what helps gives others the confidence that you’ll find a way to push through and solve the problems that your company will inevitably face as it grows.

Practice your presentation – A saying that’s always stuck with me is “We don’t rise to the level of our expectations; we fall to the level of our training.” In the case of pitching, this means putting in the work – figuring out concise answers to questions, creating logical transitions from section to section, committing particular phrases to memory – so that you feel confident and relaxed talking about your company for 30 seconds or 30 minutes no matter what the circumstances.

Read more: Stryker Buys OrthoSensor and Its Knee Surgery Sensor Technology Verasense

Make relationships the goal, not the prize – We started doing better at these events when I started focusing on what we can take away from an event regardless of where we place after a three-minute presentation. In that regard, while we’re proud to have AiQ’s Smart Clothing prize, the real goal was to earn an opportunity to work on a long-term basis with Nadia, Satya, and Steven at AiQ. Their involvement and materials could really help improve both our current knee treatment device and future applications of our core technology to other rehabilitation challenges throughout the body.

THANK YOU FOR THE INTERESTING INSIGHTS AND WE SHALL KEEP WATCHING YOUR NEXT BIG STEPS!

Visit Articulate Labs and learn more about their KNEESTIM- a light and form-fitting device that patients can use for muscle strengthening and re-education at home while they go about their normal day-to-day activities.

Join the Smart Clothing Challenge. Submit your solution free of charge. The top selected finalists will be invited to present their solutions live at HANNOVER MESSE 2022.

Don´t miss your chance!

Anytime the dispenses need to be refilled, the user takes one of the pills. The pill then travels down their digestive system until it reaches the point where the device is implanted near their small intestine. The device then uses the power of magnets to rotate the capsule into position and then punctures it with a retractable needle and pumps the refill of insulin into a reservoir, reports EndGadget.

One of the most convenient things about this system is that the dispenser charges wirelessly, limiting the number of interventions a doctor needs to maintain the device. Once the capsule is empty, it continues its travel down the digestive system until the user releases it with his stool.

Read more: This Coin-Sized Smart Patch Delivers Insulin as Blood Sugar Increases

The researchers tested their device on three diabetic pigs. They found the system could successfully manage their insulin levels for several hours. In some instances, they found bodily fluids from the pigs would leak into the robot. So as a next step, the team is working on sealing the device better.

Everything that happens in the brain is a result of neurons sending and receiving signals in complex networks that are not completely understood by scientists. These networks are what allow us to pick up a cup of coffee, laugh at a joke or stand up from a chair. When some neurons do not send and receive signals properly, it can lead to problems such as epilepsy, depression, addiction, and chronic pain.

Read more: Innovative Brain Implant Reads and Stimulates Brain to Improve Parkinson’s Treatment

University of Arizona engineering researchers, led by biomedical engineering professor and Craig M. Berge Faculty Fellow Philipp Gutruf, are creating new tools for a method called optogenetics, which shines light at specific neurons in the brain to excite or suppress activity.

Optogenetics experiments are aimed at increasing understanding of how the brain works, allowing scientists to develop and test potential cures for illnesses such as neurodegenerative diseases, reports Emily Dieckman in the University of Arizona News.

In a new paper published in PNAS, UArizona researchers collaborated with researchers at Northwestern University to demonstrate an untethered light delivery tool to enable seamless optogenetics in the brain.

While this technique has huge potential to treat diseases on a neurological basis, the invasive nature of the current methodology is a major stumbling block. The light source developed at the University of Arizona aims to change that, and bring us a little closer to clinical optogenetics.

“This technique means we can use optogenetics without having to penetrate the skull or brain tissue, making it much less invasive,” said Jokubas Ausra, a biomedical engineering doctoral student in the Gutruf Lab and the first author of the paper.

Tiny Device, Big Results

In the new paper, Gutruf and his team report on the first wireless transcranial optogenetic simulation device that can send light through the skull rather than physically penetrating the blood-brain barrier. The transcranial technique is done using a wireless and battery-free device that's as thin as a sheet of paper and about half the diameter of a dime, implanted just under the skin.

“This is significant because when optogenetics become available for humans, we have technology that enables seamless light delivery to neurons in the brain or spine,” said Gutruf, who is also a member of the university's BIO5 Institute. “This means we have a precursor technology that could someday help manage conditions like epilepsy or chronic pain without invasive surgery and chronic use of drugs.”

Read more Wise Therapeutics and Soterix Announce Results of Their Collaborative Study Combining Digital Therapy With Neurostimulation Device

Speeding Up Future Progress

There is still a long way to go before the technology is available to humans. In particular, progress must be made on methods for introducing light-sensitive proteins into the human brain and periphery.

“This tool allows scientists to do a wide range of experiments that were previously not possible,” Gutruf said. “These possibilities enable the scientific community to make faster progress to uncover the working principles of the brain and develop and test treatments in accurate environments. This is important for many areas – for example, enabling drug-free pain therapies to beat the opioid crisis.”

LifeProof, a San Diego-based mobile phone cases and accessories maker, is making eco-friendly cases for Apple Watch, AirPods, and AirPods Pro and Eco-Friendly Band for Apple Watch, using ocean-based recycled plastic. In just over a year, more than 37,500 pounds of ocean-based plastic have been repurposed into LifeProof cases.

Read more: Apple Watch’s Future Band Design Could Boost Battery Life

"LifeProof was born from the ocean with waterproof cases, and it is our responsibility to protect those waters that are so dear to us," said Jim Parke, LifeProof CEO.  "These new designs align with everything that we stand for – uncompromised protection and a dedication to help preserve our ocean by building cases from ocean-based recycled plastic.”

Dive into sustainable style with the latest LifeProof accessories for Apple Watch, Apple AirPods, and Apple AirPods Pro, says a press release.

Synchronize your high-tech timepiece to Pacific Sustainability Time with the Eco-Friendly Case for Apple Watch 4/5/6/SE 40mm and 44mm. It delivers a form-fitting line of defense for the display and edges and is made with 85 percent ocean-based recycled plastic. Health monitors, activity trackers, dials, and buttons – everything you love about your watch works just the same with the case.

Combine protection with a sustainable band for the perfect duo. Slip into something more comfortable and sustainable with the LifeProof Band for Apple Watch 38/40 mm. Made from 99 percent ocean plastic yarn, it's easy on the environment and feels good on your wrist all day long. It pairs seamlessly with your watch, connects with a buckle closure, and resists both wear and fading.

Keep your charging case safe from calamities with the Eco-Friendly Case for Apple AirPods and Eco-Friendly Case for Apple AirPods Pro. Built from 75 percent ocean-based recycled plastic, each case delivers edge-to-edge protection. Outfitted with a quick clip carabiner, it's easy to attach to a bag or keyring.

Read more: PlusUs Introduces First-Ever Flexible Wireless Charging Pad Made of Eco-Friendly Materials

In line with its corporate mission of giving back, LifeProof is inviting its consumers to make a difference, too. In partnership with Water.org, Coral Reef Alliance, American Rivers, and Oceana, LifeProof will donate for every registered purchase to support a healthier future for our world's water.

Eco-Friendly cases for Apple Watch, LifeProof Band, and cases for Apple AirPods and Apple AirPods Pro are available now on the lifeproof website.

Researchers at the University of Eastern Finland and Kuopio University Hospital have developed a wearable device that can measure the occurrence and severity of myoclonic jerks, which are sudden muscle movements experienced by patients with progressive myoclonic epilepsy.

Read more: ULTEEM: Noninvasive Epilepsy Monitoring Wearable That Attaches To Any Ordinary Eyeglasses

The method used in the study was based on the measurement of electrical neuromuscular function and movement, and it corresponded well to an assessment performed by an experienced physician. The findings were recently published in Clinical Neurophysiology.

Patients with progressive myoclonic epilepsy (EPM1) suffer from myoclonus, i.e., sudden muscle jerks that are activated by movement and other stimuli. The severity of these myoclonic jerks varies during the day, and myoclonus can be either positive or negative. A positive myoclonus refers to a sudden contraction of a muscle, while negative myoclonus refers to loss of muscle activation, which in a worst-case scenario may lead to the fall of a patient, for example.

The aim of this study was to develop and test a wearable technology-based method for assessing myoclonus symptoms in the home environment. Patients wore a small, wearable sensor on their arms for 48 hours, which measured their muscle function and movement. They also wrote down their own assessment of the severity of the myoclonus symptom. An algorithm that picks up the occurrence and variation of muscle jerks from the measurement data was developed to evaluate myoclonus symptoms, describing them as a myoclonus index, reports the University of Eastern Finland.

In current clinical practice, the Unified Myoclonus Rating Scale, UMRS, is used to assess myoclonus symptoms. When using the UMRS, an experienced physician views a video recording and scores the patient’s symptoms according to their severity. This UMRS assessment provides information on the occurrence of myoclonus at one point in time. The measurement-based myoclonus index developed in the study correlated well with the UMRS assessment performed by the physician. Patients’ at-home measurements showed that the measurement-based myoclonus index was able to detect variation in the occurrence of myoclonus symptoms during the day and night. The reliability of the measurement results was also supported by patients’ own, at-home assessments and reporting of their myoclonus symptoms.

According to the study, the myoclonus index can be used to reliably assess positive and negative myoclonus in patients with EPM1. This assessment correlates well with the assessment performed by an experienced physician, and also makes it possible to assess patients’ symptoms in the home environment.

Read more: CyMedica Launches Clinical Trial to Evaluate the Effectiveness of its Muscle Strengthening Device e-vive

The study was carried out as part of the larger New Modalities ecosystem funded by Business Finland, involving three universities and eight companies in Finland. The ecosystem is coordinated by Orion Corporation.

Epilepsy is a central nervous system (neurological) disorder in which brain activity becomes abnormal, causing seizures or periods of unusual behavior, sensations, and sometimes loss of awareness.

Read more: Purdue Researchers Develop Wearable That May Help Prevent Sudden Death From Epilepsy

Treatments include:

• Anti-epileptic drugs (AEDs)
• Surgery to remove a small part of the brain that's causing the seizures
• A procedure to put a small electrical device inside the body that can help control seizures
• A special diet (ketogenic diet) that can help control seizures

Drug-resistant epilepsy, also known as intractable epilepsy or refractory epilepsy, is defined as the failure of at least two anti-seizure drugs.

NeuroPace, a California-based MedTech company has developed the RNS system, an implantable neuromodulation device for treating drug-resistant epilepsy. It is the only FDA-approved epilepsy device that delivers personalized treatment by responding to abnormal brain activity and provides EEG data that can help improve patient care, reports NuroPace.

“The RNS System’s brain-responsive platform delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients suffering from drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders,” Martha Morrell, Chief Medical Officer at NeuroPace, told Medgadget’s Conn Hastings.

The RNS System opens new possibilities for adults with focal drug-resistant epilepsy. The device responds to your unique brain activity and gives your doctor valuable information to help personalize your epilepsy treatment.

Read more: Medtronic to Launch Deep Brain Simulation for Medically-Refractory Epilepsy in the U.S.

Benefits of the RNS system:

Fewer seizures. In a real-world study, RNS System patients reported experiencing fewer seizures.

Lower SUDEP rate. SUDEP is the sudden, unexpected death of someone with epilepsy, who was otherwise healthy.

Improved health and wellness. In a clinical study of the RNS System, patients reported significant quality of life improvements.